To include your compound in the COVID-19 Resource Center, submit it here.

Cor's new anti-platelet play

In the search for better oral anti-platelet drugs, oral platelet inhibition based on GPIIb/IIIa antagonists has proven to be more difficult than expected. Cor Therapeutics Inc. is one of the few remaining companies with an oral GPIIb/IIIa

Read the full 373 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE